The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Human equilibrative nucleoside transporter 1 (hENT1) in gemcitabine and FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin)-treated patients with metastatic pancreatic cancer: The randomized phase II PAN1 study.
Yu Jo Chua
No relevant relationships to disclose
Christos Stelios Karapetis
No relevant relationships to disclose
Val Gebski
No relevant relationships to disclose
Rachel O'Connell
No relevant relationships to disclose
Stephen Begbie
No relevant relationships to disclose
Louise M. Nott
Honoraria - Roche; Sanofi
Michelle F. Cronk
No relevant relationships to disclose
Craig Underhill
No relevant relationships to disclose
Ehtesham A. Abdi
No relevant relationships to disclose
Thomas Van Hagen
No relevant relationships to disclose
Nicole Wong
No relevant relationships to disclose
Merryn Hall
No relevant relationships to disclose
Danielle Angela Ferraro
No relevant relationships to disclose
Katrin Marie Sjoquist
No relevant relationships to disclose
Cheryl Santos
No relevant relationships to disclose
John Robert Mackey
No relevant relationships to disclose
David Goldstein
Consultant or Advisory Role - Celgene (U)
Research Funding - Celgene